Skip to main content

Table 3 Characteristics of children receiving ART (n = 54)

From: Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis

  At clinic enrollment At ART initiationa At study enrollment
Median age (yrs) (IQR) 3.6 (1.5, 7.7) 3.8 (2.0, 8.0) 4.5 (2.7, 8.6)
Median WAZ (IQR) b -2.7 (-3.5, -1.5) -2.5 (-3.9, -1.8) -2.4 (-3.2, -1.5)
   WAZ <-2 27 (61.4) 28 (70.0) 26 (60.5)
   WAZ ≥-2 17 (38.6) 12 (30.0) 17 (39.5)
Median CD4 + T cell % (IQR) 14.0 (9.2, 19.0) 12.4 (9.2, 18.6) 28.6 (23.5, 36.1)
Median CD4 + T cell count (IQR) 505 (281, 985) 368 (219, 559) 973 (466, 1522)
   Severe immunodeficiencyc 16 (50) 24 (63) 2 (5)
Median total lymphocyte count (IQR) 3194 (1948, 5351) 2747 (1634, 5351) 3372 (1862, 5276)
Median hemoglobin (IQR) 10.6 (10.0, 11.7) 10.8 (10.0, 12.0) 11.9 (10.6, 12.3)
   Hemoglobin <8 gm/dL 1 (2.0) 0 (0) 4 (8.9)
   Hemoglobin ≥8 gm/dL 49 (98.0) 36 (100.0) 41 (91.1)
WHO stage    
   1 2 (5.1) 2 (7.1) 6 (17.7)
   2 9 (23.1) 1 (3.6) 6 (17.7)
   3 22 (56.4) 20 (71.4) 20 (58.8)
   4 6 (15.4) 5 (17.9) 2 (5.9)
ART regimen    
   AZT/3TC/EFV --- 12 (26.1) 11 (42.3)
   AZT/3TC/NVP --- 11 (23.9) 7 (26.9)
   d4T/3TC/EFV --- 5 (10.8) 2 (7.7)
   d4T/3TC/NVP --- 18 (39.1) 6 (23.1)
  1. ART = antiretroviral therapy; IQR = interquartile range; WAZ = weight-for-age Z score; WHO = World Health Organization; AZT = zidovudine; 3TC = lamivudine; EFV = efavirenz; NVP = nevirapine; d4T = stavudine
  2. a7 children transferred to Macha and had already initiated ART
  3. bfor children <10 yrs old
  4. csevere immunodeficiency defined by age according to WHO guidelines